Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00559871 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

A Phase 2 study of Parkinson's Disease, sponsored by Juvantia Pharma.

Completed
Registry status
Phase 2
Development phase
180
Enrollment target
20
Study locations

NCT00559871 is a Phase 2 study of Parkinson's Disease that has completed, run by Juvantia Pharma. The registered enrollment target is 180 participants, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00559871, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Juvantia Pharma.

COMPLETED
Registry status
Phase 2
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG fipamezole

Study Locations (20)

Florida

  • Parkinson's Disease and Movement Disorder Center - Boca Raton
  • Sunrise Clinical Research - Hollywood
  • Pharmax Research Clinic - Miami
  • University of Miami - Miami
  • Collier Neurological Clinic - Naples
  • University of South Florida, Parkinson's Disease and Movement Center - Tampa

California

  • Parkinson and Movement Disorder Institute - Fountain Valley
  • University of California Irvine - Irvine
  • Coastal Neurological Medicine Group - La Jolla

Alabama

  • University of Alabama at Birmingham - Birmingham
  • Neurology Clinic PC - Northport

Georgia

  • Emory Healthcare - Atlanta
  • Medical College of Georgia - Augusta

Arizona

  • University of Arizona Health Sciences Center - Tucson

Colorado

  • Colorado Neurological Institute - Englewood

Illinois

  • Rush University Medical Center - Chicago

Kansas

  • Parkinson Disease Center - University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2007-10
Est. Completion 2009-05
Phase Phase 2

Sponsor

Juvantia Pharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00559871

The ClinicalTrials.gov registry entry for NCT00559871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (72% lower). The listed sponsor is Juvantia Pharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which fipamezole is the first listed.

NCT00559871 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT00559871 about?

NCT00559871 is a clinical study titled "Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease". The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.

What is the current status of trial NCT00559871?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2007-10. Estimated completion is 2009-05.

What conditions does trial NCT00559871 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT00559871?

The interventions under investigation include: fipamezole (DRUG).

Who is sponsoring clinical trial NCT00559871?

This trial is sponsored by Juvantia Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00559871 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.